ScholarIQanswers from OpenAlex & ORCID
Nanxin Li
ResearcherPublications, citations & collaboration network
Nanxin Li is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nanxin Li have?
ScholarIQindexed works
Nanxin Li has 240 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nanxin Li have?
ScholarIQcitation count
Nanxin Li has 22,755 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nanxin Li?
ScholarIQh-index
Nanxin Li has an h-index of 45 in OpenAlex.
What is the i10-index of Nanxin Li?
ScholarIQi10-index
Nanxin Li has an i10-index of 103 in OpenAlex.
What is the ORCID of Nanxin Li?
ScholarIQorcid
The ORCID for Nanxin Li is on the source record.
What is the OpenAlex record for Nanxin Li?
ScholarIQopenalex
The OpenAlex for Nanxin Li is on the source record.
What are the most-cited papers on Nanxin Li?
ScholarIQmost cited works
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky, K. Venkatesan, Adam A. Margolin, Sung Joon Kim, Christopher J. Wilson, Joseph Lehár, Gregory V. Kryukov, Dmitriy Sonkin, Anupama Reddy, Manway Liu, Lauren Murray, Michael F. Berger, John E. Monahan, Paula Morais, Jodi Meltzer, Adam Korejwa, Judit Jané‐Valbuena, Felipa Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying Karen Yu, Jianjun Yu, Peter Aspesi, Melanie de Silva, Kalpana Jagtap, Michael D. Jones, Li Wang, Charlie Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura E. MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey Gabriel, Gad Getz, Kristin Ardlie, Vivien W. Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter M. Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael Morrissey, William R. Sellers, Robert Schlegel, Levi A. Garraway
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C. Lee, Justin F. Gainor, Adam Crystal, Pierre‐Yves Michellys, Mark M. Awad, Noriko Yanagitani, Sung Joon Kim, AnneMarie Culazzo Pferdekamper, Jie Li, Shailaja Kasibhatla, Frank F. Sun, Xiuying Sun, Su Hua, Peter McNamara, Sidra Mahmood, Elizabeth L. Lockerman, Naoya Fujita, Makoto Nishio, Jennifer L. Harris, Alice T. Shaw, Jeffrey A. Engelman
Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje, Wei Pei, Bei Chen, Wenshuo Lu, Tetsuo Uno, Yunho Jin, Tao Jiang, Sung Joon Kim, Nanxin Li, Markus Warmuth, Yelena Sarkisova, Frank F. Sun, Auzon Steffy, AnneMarie Culazzo Pferdekamper, Allen G. Li, Sean B. Joseph, Young Ho Kim, Bo Liu, Tove Tuntland, Xiaoming Cui, Nathanael S. Gray, Ruo W. Steensma, Yongqin Wan, Jiqing Jiang, Greg Chopiuk, Jie Li, W. Perry Gordon, Wendy Richmond, Kevin C. Johnson, Jonathan Chang, Todd Groessl, You-Qun He, Andrew Phimister, J. Alex Aycinena, Christian C. Lee, Badry Bursulaya, Donald S. Karanewsky, H. Martin Seidel, Jennifer L. Harris, Pierre‐Yves Michellys